Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Business Overview: The Company is a medical device manufacturer. This period includes the impact of a tax-free stock-for-stock merger with Target Therapeutics, Inc., completed on April 8, 1997, accounted for as a pooling-of-interests. Consequently, prior period financial statements have been restated to include Target's results.
Key Financial Metrics
| Metric (in thousands) | Q3 1997 | Q3 1996 | 9 Months 1997 | 9 Months 1996 |
|---|---|---|---|---|
| Net Sales | $474,773 | $395,788 | $1,379,053 | $1,118,578 |
| Gross Profit | $338,866 | $284,564 | $990,634 | $814,013 |
| Gross Margin % | 71.4% | 71.9% | 71.8% | 72.8% |
| Operating Income | $124,351 | $109,123 | $218,294 | $189,799 |
| Net Income | $88,405 | $71,234 | $136,945 | $86,513 |
| Diluted EPS | $0.44 | $0.36 | $0.69 | $0.43 |
| Cash & Equivalents (End of Period) | $54,269 | $69,999 | N/A | |
| Short-term Investments | $42,670 | $45,606 | ||
| Working Capital | $332,850 | $335,001 | N/A | |
| Total Debt (Current + Long-term) | $415,763 | $240,556 |
Note: Debt figures include $365.9M in borrowings due within one year (primarily commercial paper) and $49.9M in long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% in Q3 and 23% for the nine-month period. Excluding foreign currency impacts, sales growth was approximately 24% (Q3) and 27% (9 months).
- Profitability: Net income rose 24% in Q3 and 58% for the nine-month period. However, this includes significant special charges. Adjusted net income (excluding special charges) increased 19% for the nine-month period.
- Special Charges: The Company recorded $157.8 million in special charges for Q3 1997 (totaling $214.5 million for the nine months). These relate to the Target merger integration, workforce reductions, facility rationalization, and asset writedowns.
- Margin Compression: Gross margin decreased slightly (71.9% to 71.4% in Q3) due to product mix shifts, pricing pressure, and inventory reserves related to new product launches and manufacturing transfers.
- Balance Sheet: Inventories increased significantly from $236.7M to $363.0M. Accounts receivable grew from $321.0M to $385.6M, attributed to increased international sales with longer payment terms.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Cost Structure: Management notes that operating results were below internal expectations due to an expense infrastructure not yet fully absorbed by revenue growth. It is expected to take several quarters to earn off the elevated cost structure.
- Capital Expenditures: The Company expects to incur approximately $80 million in capital expenditures for the remainder of 1997 for manufacturing, distribution, and global information systems.
- Liquidity: Cash and short-term investments totaled $97 million. The Company has a $500 million credit facility (with $343 million in commercial paper outstanding) and has filed a registration statement to issue up to $500 million in debt securities if needed.
Risks and Contingencies
- Legal Proceedings: The Company is involved in numerous patent infringement lawsuits (e.g., against C.R. Bard, Johnson & Johnson, Cordis, and Advanced Cardiovascular Systems). A jury verdict in June 1997 found the Company infringed a Bard patent, awarding $10.8 million in damages; the Company intends to appeal.
- Regulatory Environment: Stricter regulatory requirements and longer approval times for new products pose risks to development timelines and costs.
- Market Pressures: Consolidation among healthcare providers and managed care trends continue to exert pressure on selling prices and gross margins.
- Foreign Exchange: International revenues are subject to currency fluctuations, though the Company utilizes hedging strategies.
Investor Verification Checklist
- Merger Integration Costs: Verify the actual cash outlays for the $158 million in special charges against the estimated $80 million remaining cash outlay for integration.
- Inventory Levels: Monitor inventory reserves and turnover, as levels are high due to new product launches and manufacturing shifts; further write-downs could impact margins.
- Legal Outcomes: Track the status of the C.R. Bard appeal and the multiple patent disputes with Johnson & Johnson and Cordis, as adverse rulings could result in significant damages or injunctions.
- Debt Utilization: Confirm the utilization of the $500 million credit facility and the potential issuance of new debt securities to fund strategic initiatives.
- Operating Leverage: Assess whether revenue growth in subsequent quarters is sufficient to absorb the elevated fixed cost structure mentioned by management.